Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 61 of 520 for:    melanoma phase III

Melanoma Patients Immunized With Natural DenDritic Cells (MIND-DC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02993315
Recruitment Status : Recruiting
First Posted : December 15, 2016
Last Update Posted : July 25, 2018
Sponsor:
Collaborators:
Zorginstituut Nederland
ZonMw: The Netherlands Organisation for Health Research and Development
Information provided by (Responsible Party):
Radboud University

Brief Summary:
The aim of this study is to determine whether adjuvant treatment with nDC vaccination, after complete radical lymph node dissection or sentinel node procedure in stage IIIB and IIIC melanoma patients, improves recurrence-free survival (RFS) as compared to treatment with matching placebo.

Condition or disease Intervention/treatment Phase
Melanoma (Skin) Biological: nDC vaccination Biological: placebo injection Phase 3

Detailed Description:
This is a phase 3, randomized, double-blind, interventional study of nDC vaccination versus placebo. Dendritic cell-based immunotherapy consists of antigen-loaded autologous DC that are administered to patients with the intention of inducing antigen-specific T and B cell responses and proved safe with minimal side effects. Natural DC (nDC) consist of plasmacytoid DC and myeloid DC. Subjects will be randomized 2:1 and stratified by stage of disease, adjuvant radiotherapy, BRAF mutation status, HLA-type and nDC production centre. The treatment will be continued for a maximum of 1.5 years or until recurrence of disease, unacceptable toxicity or withdrawal from the study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 210 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double-‐Blind, Placebo‐Controlled Phase III Study to Evaluate Active Immunization in Adjuvant Therapy of Patients With Stage IIIB and IIIC Melanoma With Natural Dendritic Cells Pulsed With Synthetic Peptides.
Study Start Date : October 2016
Estimated Primary Completion Date : October 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Melanoma

Arm Intervention/treatment
Experimental: nDC vaccination arm
Patients in the nDC vaccination arm will receive a maximum of 3 cycles each consisting of 3 nDC injections intranodally (3-8x10^6 nDC).
Biological: nDC vaccination
Placebo Comparator: placebo arm
Patients will receive a maximum of 3 cycles each consisting of 3 placebo injections intranodally.
Biological: placebo injection



Primary Outcome Measures :
  1. Recurrence-free survival rate [ Time Frame: 2 years ]
    The primary objective of this study is to determine whether adjuvant nDC vaccination, after complete radical lymph node dissection or sentinel node procedure in stage IIIB and IIIC melanoma patients, improves 2-year RFS rate as compared to treatment with matching placebo. Defined as the percentage of patients who are alive and without recurrence of melanoma 2 years after randomization.


Secondary Outcome Measures :
  1. Recurrence-free survival [ Time Frame: 2 years and 5 years ]
    Median RFS duration will be assessed by physical examination and CT of the chest and abdomen every 3-12 months, or on clinical indication, during 5 years.

  2. Overall survival [ Time Frame: 2-years and median ]
  3. Tumor specific T-cell response [ Time Frame: week 1, week 9, week 10, week 31, week 39, week 57, week 65, week 78, month 24, month 60 ]
  4. Quality of Life Questionnaires [ Time Frame: baseline, week 14, week 26, month 12, month 24, month 36, month 60 ]
  5. Costs (direct and indirect) of treatment [ Time Frame: 2 years ]
  6. QALY [ Time Frame: 2 years ]
    A cost-effectiveness acceptability curve will be derived that is able to evaluate efficiency by using different tresholds (willingness to pay) for a QALY.

  7. Adverse Events related to treatment [ Time Frame: 1,5 year ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Eligibility Criteria:

  • at least 18 years of age.
  • Histologically confirmed stage III cutaneous melanoma, classified as IIIB or IIIC disease (AJCC 2009). Patients with completely resected in-transit and/or satellite metastases and patients with unknown primary melanoma are allowed in this trial.
  • Radical lymph node dissection involved site with complete resection or sentinel node procedure (in case of patients without RLND because of limited sentinel-node positive disease) of melanoma as documented on the operating report and pathology report with at least the minimal levels excised as stated in national guidelines.
  • Radical lymph node dissection involved site with complete resection or sentinel node procedure (in case of patients without RLND because of limited sentinel-node positive disease) must be performed within 12 weeks prior to start of study.
  • Recovered from definitive surgery (e.g. no uncontrolled wound infections or indwelling drains).
  • Absence of distant metastases must be documented by a CT scan of the chest and abdomen (including pelvis) or a Positron Emission Tomography (PET) scan, the scan should have been performed within 6 weeks before surgery or after surgery prior to inclusion. In addition, a physical exam after surgery must be performed also excluding distant metastases.
  • No clinical evidence for brain metastasis. If brain metastases are clinically suspected, a CT or Magnetic Resonance Imaging (MRI) scan of the brain must exclude brain metastases.
  • World Health Organization (WHO) performance status of 0 or 1 at time of randomization.
  • Adequate hematologic, renal and liver function as defined by laboratory values performed within 4 weeks of randomization.
  • No second malignancy in the previous 5 years, with the exception of adequately treated carcinoma in-situ and basal or squamous cell carcinoma of the skin.
  • No concomitant use of immunosuppressive drugs orally or intravenously. Topical and intranasal steroids are permitted.
  • No uncontrolled infectious disease, i.e. negative testing for HIV, HBV, HCV and syphilis.
  • No autoimmune disease such as, but not limited to, inflammatory bowel disease, multiple sclerosis, and lupus. Patients with type 1 diabetes mellitus, hypothyroidism after autoimmune thyroiditis and skin disorders are not excluded.
  • No serious (bleeding and clotting) condition that may interfere with safe leukapheresis.
  • No pregnant or lactating women.
  • No Women Of Child-Bearing Potential (WOCBP) who are unwilling or unable to use an acceptable method to avoid pregnancy for up to 8 weeks after the last administration of the treatment. WOCBP include any female who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation or bilateral oophorectomy) or is not postmenopausal [defined as amenorrhea > 12 consecutive months].
  • Patients must have absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions must be discussed with the patient before registration in the trial.
  • Expected adequacy of follow-up.
  • Written informed consent.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02993315


Contacts
Layout table for location contacts
Contact: Winald Gerritsen, Prof. MD. +31243618800 MINDstudie.TIL@radboudumc.nl
Contact: Martine Bloemendal, MD +31243618800 MINDstudie.TIL@radboudumc.nl

Locations
Layout table for location information
Netherlands
NKI-AvL Not yet recruiting
Amsterdam, Netherlands
Contact: John Haanen, Prof. MD.         
VUmc Not yet recruiting
Amsterdam, Netherlands
Contact: Alfons van den Eertwegh, MD         
Radboudumc Recruiting
Nijmegen, Netherlands
Contact: Winald Gerritsen, Prof. MD.    +31243618800    MINDstudie.TIL@radboudumc.nl   
ErasmusMC Not yet recruiting
Rotterdam, Netherlands
Contact: Willem Kruit, MD         
Isala klinieken Recruiting
Zwolle, Netherlands
Contact: Jan Willem de Groot, MD.         
Sponsors and Collaborators
Radboud University
Zorginstituut Nederland
ZonMw: The Netherlands Organisation for Health Research and Development
Investigators
Layout table for investigator information
Principal Investigator: Jolanda de Vries, Prof. dr. Radboud University

Layout table for additonal information
Responsible Party: Radboud University
ClinicalTrials.gov Identifier: NCT02993315     History of Changes
Other Study ID Numbers: NL55823.000.15
First Posted: December 15, 2016    Key Record Dates
Last Update Posted: July 25, 2018
Last Verified: July 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Additional relevant MeSH terms:
Layout table for MeSH terms
Melanoma
Nevi and Melanomas
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Nerve Tissue
Vaccines
Immunologic Factors
Physiological Effects of Drugs